Literature DB >> 3463989

Physical association of the human base-excision repair enzyme uracil DNA glycosylase with the 70,000-dalton catalytic subunit of DNA polymerase alpha.

G Seal, M A Sirover.   

Abstract

A monoclonal antibody prepared against a partially purified human uracil DNA glycosylase was found, on further purification of the enzyme, to be inactive against the glycosylase. However, immunoreactivity was observed in other protein fractions that contained DNA polymerase activity. The immunoreactive protein was purified to homogeneity and identified as a catalytic subunit of DNA polymerase alpha by molecular mass, by aphidicolin sensitivity, and by recognition by a monoclonal antibody against human KB cell DNA polymerase alpha. Our monoclonal antibody had no effect on homogeneous human uracil DNA glycosylase activity but severely inhibited the activity of the homogeneous human DNA polymerase alpha catalytic subunit. The suspicion that the two proteins were physically associated was confirmed by finding that, on mixing the DNA polymerase alpha subunit with the glycosylase, the latter was strongly inhibited by our monoclonal antibody. These results demonstrate that this monoclonal antibody recognizes not only the DNA polymerase alpha subunit but also the uracil DNA glycosylase when it is physically attached to the polymerase subunit. These results contribute to the definition of relationships between those proteins that may comprise the human base-excision repair multienzyme complex.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3463989      PMCID: PMC386770          DOI: 10.1073/pnas.83.20.7608

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Co-operative mutagenic actions of bisulfite and nitrogen nucleophiles.

Authors:  H Hayatsu
Journal:  J Mol Biol       Date:  1977-09       Impact factor: 5.469

Review 2.  Apurinic sites as mutagenic intermediates.

Authors:  L A Loeb
Journal:  Cell       Date:  1985-03       Impact factor: 41.582

3.  Induction of DNA polymerase in mouse L cells.

Authors:  L M Chang; M Brown; F J Bollum
Journal:  J Mol Biol       Date:  1973-02-15       Impact factor: 5.469

4.  Mammalian mutator mutant with an aphidicolin-resistant DNA polymerase alpha.

Authors:  P K Liu; C C Chang; J E Trosko; D K Dube; G M Martin; L A Loeb
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

Review 5.  DNA repair enzymes.

Authors:  T Lindahl
Journal:  Annu Rev Biochem       Date:  1982       Impact factor: 23.643

Review 6.  The initiation of DNA excision-repair.

Authors:  G W Teebor; K Frenkel
Journal:  Adv Cancer Res       Date:  1983       Impact factor: 6.242

Review 7.  Cellular aspects of DNA repair.

Authors:  B S Strauss
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

8.  Mutagenesis in vitro by depurination of phiX174 dna.

Authors:  T A Kunkel; C W Shearman; L A Loeb
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

9.  Isolation and characterization of monoclonal antibodies directed against the DNA repair enzyme uracil DNA glycosylase from human placenta.

Authors:  P Arenaz; M A Sirover
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

10.  On the fidelity of DNA replication. Studies with human placenta DNA polymerases.

Authors:  G Seal; C W Shearman; L A Loeb
Journal:  J Biol Chem       Date:  1979-06-25       Impact factor: 5.157

View more
  10 in total

1.  Mutations in active-site residues of the uracil-DNA glycosylase encoded by vaccinia virus are incompatible with virus viability.

Authors:  K S Ellison; W Peng; G McFadden
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

2.  Immunological lesions in human uracil DNA glycosylase: association with Bloom syndrome.

Authors:  G Seal; K Brech; S J Karp; B L Cool; M A Sirover
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

3.  Vaccinia virus uracil DNA glycosylase has an essential role in DNA synthesis that is independent of its glycosylase activity: catalytic site mutations reduce virulence but not virus replication in cultured cells.

Authors:  Frank S De Silva; Bernard Moss
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Requirement for uracil-DNA glycosylase during the transition to late-phase cytomegalovirus DNA replication.

Authors:  C T Courcelle; J Courcelle; M N Prichard; E S Mocarski
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Determination and analysis of the complete nucleotide sequence of human herpesvirus.

Authors:  J Nicholas
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

6.  Characterization of the uracil-DNA glycosylase activity of Epstein-Barr virus BKRF3 and its role in lytic viral DNA replication.

Authors:  Chih-Chung Lu; Ho-Ting Huang; Jiin-Tarng Wang; Geir Slupphaug; Tsai-Kun Li; Meng-Chuan Wu; Yi-Chun Chen; Chung-Pei Lee; Mei-Ru Chen
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

7.  Human uracil-DNA glycosylase complements E. coli ung mutants.

Authors:  L C Olsen; R Aasland; H E Krokan; D E Helland
Journal:  Nucleic Acids Res       Date:  1991-08-25       Impact factor: 16.971

8.  Human cytomegalovirus uracil DNA glycosylase is required for the normal temporal regulation of both DNA synthesis and viral replication.

Authors:  M N Prichard; G M Duke; E S Mocarski
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

9.  Characterisation of the substrate specificity of homogeneous vaccinia virus uracil-DNA glycosylase.

Authors:  Natale Scaramozzino; Guenhael Sanz; Jean Marc Crance; Murat Saparbaev; Robert Drillien; Jacques Laval; Bodil Kavli; Daniel Garin
Journal:  Nucleic Acids Res       Date:  2003-08-15       Impact factor: 16.971

10.  Molecular cloning of human uracil-DNA glycosylase, a highly conserved DNA repair enzyme.

Authors:  L C Olsen; R Aasland; C U Wittwer; H E Krokan; D E Helland
Journal:  EMBO J       Date:  1989-10       Impact factor: 11.598

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.